Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Radiation Dose in Cardiac Imaging: How Should It Affect Clinical Decisions?
Shapiro, Brian P. , Mergo, Patricia J. , Snipelisky, David , Kantor, Birgit, Gerber, Thomas C.

American Journal of Roentgenology | February 23, 2013 | Volume: 200 | Issue: 3 | Pages: 508-514

10.2214/ajr.12.9773 | PMID 23436838 Get It

Diffuse Diseases of the Myocardium: MRI-Pathologic Review of Cardiomyopathies With Dilatation
Giesbrandt, Kirk J., Bolan, Candice W. , Shapiro, Brian P. , Edwards, William D. , Mergo, Patricia J.

American Journal of Roentgenology | February 23, 2013 | Volume: 200 | Issue: 3 | Pages: W274-W282

10.2214/ajr.12.9634 | PMID 23436872 Get It

Diffuse Diseases of the Myocardium: MRI-Pathologic Review of Nondilated Cardiomyopathies
Giesbrandt, Kirk J., Bolan, Candice W. , Shapiro, Brian P. , Edwards, William D. , Mergo, Patricia J.

American Journal of Roentgenology | February 23, 2013 | Volume: 200 | Issue: 3 | Pages: W266-W273

10.2214/ajr.12.9633 | PMID 23436871 Get It

Invasive Micropapillary Carcinoma of the Breast: Imaging Features With Clinical and Pathologic Correlation
Jones, Katie N., Guimarães, Luís , Reynolds, Carol, Ghosh, Karthik, Glazebrook, Katrina N. , Degnim, Amy C.

American Journal of Roentgenology | February 23, 2013 | Volume: 200 | Issue: 3 | Pages: 689-695

10.2214/ajr.12.8512 | PMID 23436864 Get It

Caregivers of Patients With Cancer Fatigue
Clark, Matthew M. , Atherton, Pamela J., Rausch, Sarah M., Frost, Marlene H., Hanson, Jean, Garces, Yolanda I. , Brown, Paul D. , Sloan, Jeff A. , Richardson, Jarrett W., Piderman, Katherine M. , Rummans, Teresa A. , Atherton, Philip J. , Atherton, Pamela J., Lapid, Maria I. , Cheville, Andrea , Atherton, Philip J.

American Journal of Hospice and Palliative Medicine® | February 23, 2013 | Volume: 31 | Issue: 2 | Pages: 121-125

10.1177/1049909113479153 | PMID 23434836 Get It

Fatigue is the problematic symptom identified by patients with cancer. However, fatigue has not been widely examined in caregivers of patients with cancer. In this study, 131 caregivers of patients diagnosed with advanced stage cancer and actively receiving radiotherapy reported experiencing the most difficulties with fatigue (mean 46.9; on a 0-100 scale, with a 10-point difference having clinical meaning) at baseline and at a 6-month follow-up (mean 48.3). This is in sharp contrast to other domains of quality of life and functioning being rated in the 60s, 70s and 80s by the caregivers of patients with cancer. Given the level of fatigue reported by the caregivers of patients with cancer, if confirmed by other investigators in larger and more diverse samples, interventions targeting caregiver fatigue should be explored.
Implantable Cardioverter Defibrillators in Patients with Cardiac Amyloidosis
Lin, Grace , Dispenzieri, Angela , Kyle, Robert A. , Grogan, Martha , Brady, Peter A. , Dispenzieri, Angela

Journal of Cardiovascular Electrophysiology | February 22, 2013 | Volume: 24 | Issue: 7 | Pages: 793-798

10.1111/jce.12123 | PMID 23489983 Get It

ICD in Cardiac AmyloidosisBackgroundCardiac amyloidosis (CA) is associated with increased risk of sudden cardiac arrest. Although ICD therapy improves survival in patients with cardiomyopathy due to other etiologies, the benefit of ICD therapy in patients with CA is unclear in large part due to limited data on the precise mechanism of sudden cardiac arrest and selection of patients with cardiac amyloidosis for ICD therapy.ObjectiveThe objective was to determine the benefit of ICD therapy in cardiac amyloidosis.MethodsWe reviewed all ICD implant indications, procedures, and therapies, of CA patients evaluated at Mayo Clinic between 2000 and 2009.ResultsA total of 53 patients with CA (33 AL, 10 senile, 9 familial, and 1 AA) who underwent ICD implantation were included. Indication for ICD implantation was for primary prevention of sudden cardiac arrest in 41 (77%) patients and secondary prevention in 12 (23%) patients. The rate of appropriate ICD shocks was 32% in the first year and was observed almost exclusively in AL amyloidosis patients, occurring in 15 patients (12 AL amyloidosis, 2 senile, 1 AA). Appropriate ICD shocks were more frequent in patients with prior sudden cardiac arrest or sustained ventricular arrhythmias (secondary prevention indication), and less frequent in patients who presented with decreased ejection fraction or syncope.ConclusionsA high rate of appropriate ICD shocks was observed especially in patients with AL‐type amyloidosis. However, appropriate ICD therapy did not translate into overall survival benefit, suggesting that selection of patients with CA who might be candidates for ICD is imprecise.
Population Pharmacokinetic Model for Cancer Chemoprevention With Sulindac in Healthy Subjects
Berg, Alexander , Mandrekar, Sumithra J. , Ziegler, Katie L. Allen, Carlson, Elsa C., Szabó, Éva , Ames, M. M., Boring, Daniel, Network, ; For the Cancer Prevention, Limburg, Paul J. , Reid, Joel M. , Network, ; For the Cancer Prevention, Szabo, Eva

The Journal of Clinical Pharmacology | February 22, 2013 | Volume: 53 | Issue: 4 | Pages: 403-412

10.1002/jcph.26 | PMID 23436338 Get It

AbstractSulindac is a prescription‐based non‐steroidal anti‐inflammatory drug (NSAID) that continues to be actively investigated as a candidate cancer chemoprevention agent. To further current understanding of sulindac bioavailability, metabolism, and disposition, we developed a population pharmacokinetic model for the parent compound and its active metabolites, sulindac sulfide, and exisulind. This analysis was based on data from 24 healthy subjects who participated in a bioequivalence study comparing two formulations of sulindac. The complex disposition of sulindac and its metabolites was described by a seven‐compartment model featuring enterohepatic recirculation and is the first reported population pharmacokinetic model for sulindac. The derived model was used to explore effects of clinical variables on sulindac pharmacokinetics and revealed that body weight, creatinine clearance, and gender were significantly correlated with pharmacokinetic parameters. Moreover, the model quantifies the relative bioavailability of the sulindac formulations and illustrates the utility of population pharmacokinetics in bioequivalence assessment. This novel population pharmacokinetic model provides new insights regarding the factors that may affect the pharmacokinetics of sulindac and the exisulind and sulindac sulfide metabolites in generally healthy subjects, which have implications for future chemoprevention trial design for this widely available agent.
Incidence and Mortality of Obstructive Lung Disease in Rheumatoid Arthritis: A Population‐Based Study
Nannini, Carlotta, Medina, Yimy F. , Achenbach, Sara J., Crowson, Cynthia S. , Ryu, Jay H. , Vassallo, Robert , Gabriel, Sherine E., Matteson, Eric L. , Bongartz, Tim, Vassallo, Robert , Ryu, Jay H

Arthritis Care & Research | February 22, 2013 | Volume: 65 | Issue: 8 | Pages: 1243-1250

10.1002/acr.21986 | PMID 23436637 Get It

ObjectivePulmonary disease represents an important extraarticular manifestation of rheumatoid arthritis (RA). While the association of RA and interstitial lung disease is widely acknowledged, obstructive lung disease (OLD) in RA is less well understood. We therefore aimed to assess the incidence, risk factors, and mortality of OLD in patients with RA.MethodsWe examined a population‐based incident cohort of patients with RA and a comparison cohort of individuals without RA. OLD was defined using a strict composite criterion. Cox proportional hazards models were used to compare OLD incidence between the RA and comparator cohorts to investigate risk factors and to explore the impact of OLD on patient survival.ResultsA total of 594 patients with RA and 596 subjects without RA were followed for a mean of 16.3 and 19.4 years, respectively. The lifetime risk of developing OLD was 9.6% for RA patients and 6.2% for subjects without RA (hazard ratio [HR] 1.54, 95% confidence interval [95% CI] 1.01–2.34). The risk of developing OLD was higher among male patients, among current or former smokers, and for individuals with more severe RA. Survival of RA patients diagnosed with OLD was worse compared to those without OLD (HR 2.09, 95% CI 1.47–2.97).ConclusionPatients with RA are at higher risk of developing OLD, which is significantly associated with premature mortality. Effective diagnostic and therapeutic strategies to detect and manage OLD in patients with RA may help to improve survival in these patients.
Systemic mastocytosis in the elderly
Butterfield, Joseph H. , Weiler, Catherine R.

American Journal of Hematology | February 22, 2013 | Volume: 88 | Issue: 5 | Pages: 406-408

10.1002/ajh.23426 | PMID 23436294 Get It

“Later onset” of systemic mastocytosis (SM) has been associated with a poorer prognosis. We examined clinical and laboratory findings, associated disorders, and survival in an older mastocytosis population. After receiving Mayo Clinic Institutional Review Board approval, we identified 42 patients aged 70 years and older at the time of diagnosis of SM. Associated disorders, cytogenetic abnormalities, laboratory findings, and survival were recorded. Only 10 patients had no associated hematologic disorder. Single or multiple chromosomal abnormalities, exclusive of the KIT Asp816Val mutation, were detected in eight patients (19%). KIT Asp816Val mutation was present in 14 patients, negative in three, and not tested in 25. Slight to marked bone marrow hypercellularity was observed in 33 patients (79%). Concurrent hematologic abnormalities included chronic myelomonocytic leukemia (n = 7), acute myelocytic leukemia (n = 1), myelodysplastic syndrome (MDS; n = 7), eosinophilia (n = 7), myelofibrosis (n = 1), myeloproliferative disorder (n = 1), multiple myeloma (n = 1), B‐cell lymphoma (n = 1), and thrombocytopenia (n = 4). Eight patients had a hematologic disorder that preceded the diagnosis of SM. Tryptase levels were elevated in 38 of 39 patients tested. Survival from the diagnosis of SM was poor for patients with associated thrombocytopenia, leukemias, and MDS. In conclusion, patients with SM diagnosed at age 70 or older have an increased risk of secondary hematologic disorders and abnormal laboratory findings. Cytogenetic abnormalities are common, and survival is short in many SM patients with associated leukemias, MDS, or eosinophilia. Am. J. Hematol. 88:406–408, 2013. © 2013 Wiley Periodicals, Inc.
Endothelial Outgrowth Cells Shift Macrophage Phenotype and Improve Kidney Viability in Swine Renal Artery Stenosis
Eirin, Alfonso , Zhu, Xiang-Yang, Li, Zilun , Ebrahimi, Behzad , Zhang, Xin , Korsmo, Michael J., Chade, Alejandro , Grande, Joseph P. , Ward, Christopher J. , Simari, Robert D., Textor, Stephen C., Lerman, Lilach O. , Tang, Hui Jun , Lerman, Amir , Eirin, Alfonso

Arteriosclerosis, Thrombosis, and Vascular Biology | February 22, 2013 | Volume: 33 | Issue: 5 | Pages: 1006-1013

10.1161/atvbaha.113.301164 | PMID 23430615 Get It

Objective— Endothelial outgrowth cells (EOC) decrease inflammation and improve endothelial repair. Inflammation aggravates kidney injury in renal artery stenosis (RAS), and may account for its persistence upon revascularization. We hypothesized that EOC would decrease inflammatory (M1) macrophages and improve renal recovery in RAS. Approach and Results— Pigs with 10 weeks of RAS were studied 4 weeks after percutaneous transluminal renal angioplasty (PTRA+stenting) or sham, with or without adjunct intrarenal delivery of autologous EOC (10×10 6 ), and compared with similarly treated normal controls (n=7 each). Single-kidney function, microvascular and tissue remodeling, inflammation, oxidative stress, and fibrosis were evaluated. Four weeks after PTRA, EOC were engrafted in injected RAS-kidneys. Stenotic-kidney glomerular filtration rate was restored in RAS+EOC, RAS+PTRA, and RAS+PTRA+EOC pigs, whereas stenotic-kidney blood flow and angiogenesis were improved and fibrosis attenuated only in EOC-treated pigs. Furthermore, EOC increased cell proliferation and decreased the ratio of M1 (inflammatory)/M2 (reparative) macrophages, as well as circulating levels and stenotic-kidney release of inflammatory cytokines. Cultured-EOC released microvesicles in vitro and induced phenotypic switch (M1-to-M2) in cultured monocytes, which was inhibited by vascular endothelial growth factor blockade. Finally, a single intrarenal injection of rh-vascular endothelial growth factor (0.05 μg/kg) in 7 additional RAS pigs also restored M1/M2 ratio 4 weeks later. Conclusions— Intrarenal infusion of EOC after PTRA induced a vascular endothelial growth factor–mediated attenuation in macrophages inflammatory phenotype, preserved microvascular architecture and function, and decreased inflammation and fibrosis in the stenotic kidney, suggesting a novel mechanism and therapeutic potential for adjunctive EOC delivery in experimental RAS to improve PTRA outcomes.